XORTX Therapeutics, Inc. (XRTX)
0.89
-0.17
(-16.04%)
USD |
NASDAQ |
Nov 19, 16:00
0.8722
-0.02
(-2.00%)
Pre-Market: 09:11
XORTX Therapeutics Cash from Operations (Quarterly) : -0.5428M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.5428M |
| June 30, 2026 | -3.250M |
| March 31, 2026 | -0.5014M |
| December 31, 2025 | -0.6762M |
| September 30, 2025 | -0.6348M |
| June 30, 2025 | -0.8198M |
| March 31, 2025 | -0.6437M |
| December 31, 2024 | -0.8188M |
| September 30, 2024 | -0.749M |
| June 30, 2024 | -0.7408M |
| March 31, 2024 | -1.304M |
| December 31, 2023 | -1.297M |
| September 30, 2023 | -1.072M |
| June 30, 2023 | -1.728M |
| March 31, 2023 | -2.484M |
| December 31, 2022 | -3.798M |
| September 30, 2022 | -0.9481M |
| June 30, 2022 | -1.862M |
| Date | Value |
|---|---|
| March 31, 2022 | -2.503M |
| December 31, 2021 | -3.136M |
| September 30, 2021 | -0.0613M |
| June 30, 2021 | -0.7021M |
| March 31, 2021 | -0.9237M |
| December 31, 2020 | 0.0269M |
| September 30, 2020 | -0.0898M |
| June 30, 2020 | -0.14M |
| March 31, 2020 | -0.3344M |
| December 31, 2019 | -0.0265M |
| September 30, 2019 | 0.0097M |
| June 30, 2019 | -0.03M |
| March 31, 2019 | -0.0882M |
| December 31, 2018 | -0.0942M |
| September 30, 2018 | -0.1523M |
| June 30, 2018 | -0.2132M |
| March 31, 2018 | -0.2567M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Lexaria Bioscience Corp. | -1.635M |
| Target Group, Inc. (Canada) | 0.2936M |
| NervGen Pharma Corp. | -9.236M |
| Milestone Pharmaceuticals, Inc. | -24.76M |
| Appili Therapeutics, Inc. | -0.5351M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.033M |
| Cash from Financing (Quarterly) | -0.0951M |
| Free Cash Flow | -5.174M |
| Free Cash Flow Per Share (Quarterly) | -0.3194 |
| Free Cash Flow to Equity (Quarterly) | -0.5758M |
| Free Cash Flow to Firm (Quarterly) | -0.5758M |
| Free Cash Flow Yield | -305.6% |